Research ArticleArticle
Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis
Mark C. Genovese, Daniel K. Braun, Janelle S. Erickson, Pierre-Yves Berclaz, Subhashis Banerjee, Michael P. Heffernan and Hilde Carlier
The Journal of Rheumatology December 2015, jrheum.140831; DOI: https://doi.org/10.3899/jrheum.140831
Mark C. Genovese
From the Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California; Eli Lilly and Company, Indianapolis, Indiana; Bristol-Myers Squibb, Princeton, New Jersey, USA. Funded by Eli Lilly and Company. M.C. Genovese has received grants and consulting support from Eli Lilly and Company. D.K. Braun, J.S. Erickson, P.Y. Berclaz, M.P. Heffernan, and H. Carlier are employees of Eli Lilly and Company and own stock or stock options in the company. S. Banerjee is a former employee of Eli Lilly and Company and owns stock in the company. M.C. Genovese, MD, James W. Raitt Professor of Medicine, Co-Chief of Division of Immunology and Rheumatology, Stanford University School of Medicine; D.K. Braun, MD, Medical Fellow; Eli Lilly and Company; J.S. Erickson, PhD, Statistician, Eli Lilly and Company; P.Y. Berclaz, MD, Senior Medical Director, Eli Lilly and Company; M.P. Heffernan, MD, Senior Medical Director, Eli Lilly and Company; H. Carlier, MD, Senior Medical Advisor, Eli Lilly and Company, Indianapolis; S. Banerjee, MD, Bristol-Myers Squibb. Address correspondence to Dr. M.C. Genovese, James W. Raitt Professor of Medicine, Co-Chief Division of Immunology and Rheumatology, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication October 1, 2015.
Daniel K. Braun
From the Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California; Eli Lilly and Company, Indianapolis, Indiana; Bristol-Myers Squibb, Princeton, New Jersey, USA. Funded by Eli Lilly and Company. M.C. Genovese has received grants and consulting support from Eli Lilly and Company. D.K. Braun, J.S. Erickson, P.Y. Berclaz, M.P. Heffernan, and H. Carlier are employees of Eli Lilly and Company and own stock or stock options in the company. S. Banerjee is a former employee of Eli Lilly and Company and owns stock in the company. M.C. Genovese, MD, James W. Raitt Professor of Medicine, Co-Chief of Division of Immunology and Rheumatology, Stanford University School of Medicine; D.K. Braun, MD, Medical Fellow; Eli Lilly and Company; J.S. Erickson, PhD, Statistician, Eli Lilly and Company; P.Y. Berclaz, MD, Senior Medical Director, Eli Lilly and Company; M.P. Heffernan, MD, Senior Medical Director, Eli Lilly and Company; H. Carlier, MD, Senior Medical Advisor, Eli Lilly and Company, Indianapolis; S. Banerjee, MD, Bristol-Myers Squibb. Address correspondence to Dr. M.C. Genovese, James W. Raitt Professor of Medicine, Co-Chief Division of Immunology and Rheumatology, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication October 1, 2015.
Janelle S. Erickson
From the Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California; Eli Lilly and Company, Indianapolis, Indiana; Bristol-Myers Squibb, Princeton, New Jersey, USA. Funded by Eli Lilly and Company. M.C. Genovese has received grants and consulting support from Eli Lilly and Company. D.K. Braun, J.S. Erickson, P.Y. Berclaz, M.P. Heffernan, and H. Carlier are employees of Eli Lilly and Company and own stock or stock options in the company. S. Banerjee is a former employee of Eli Lilly and Company and owns stock in the company. M.C. Genovese, MD, James W. Raitt Professor of Medicine, Co-Chief of Division of Immunology and Rheumatology, Stanford University School of Medicine; D.K. Braun, MD, Medical Fellow; Eli Lilly and Company; J.S. Erickson, PhD, Statistician, Eli Lilly and Company; P.Y. Berclaz, MD, Senior Medical Director, Eli Lilly and Company; M.P. Heffernan, MD, Senior Medical Director, Eli Lilly and Company; H. Carlier, MD, Senior Medical Advisor, Eli Lilly and Company, Indianapolis; S. Banerjee, MD, Bristol-Myers Squibb. Address correspondence to Dr. M.C. Genovese, James W. Raitt Professor of Medicine, Co-Chief Division of Immunology and Rheumatology, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication October 1, 2015.
Pierre-Yves Berclaz
From the Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California; Eli Lilly and Company, Indianapolis, Indiana; Bristol-Myers Squibb, Princeton, New Jersey, USA. Funded by Eli Lilly and Company. M.C. Genovese has received grants and consulting support from Eli Lilly and Company. D.K. Braun, J.S. Erickson, P.Y. Berclaz, M.P. Heffernan, and H. Carlier are employees of Eli Lilly and Company and own stock or stock options in the company. S. Banerjee is a former employee of Eli Lilly and Company and owns stock in the company. M.C. Genovese, MD, James W. Raitt Professor of Medicine, Co-Chief of Division of Immunology and Rheumatology, Stanford University School of Medicine; D.K. Braun, MD, Medical Fellow; Eli Lilly and Company; J.S. Erickson, PhD, Statistician, Eli Lilly and Company; P.Y. Berclaz, MD, Senior Medical Director, Eli Lilly and Company; M.P. Heffernan, MD, Senior Medical Director, Eli Lilly and Company; H. Carlier, MD, Senior Medical Advisor, Eli Lilly and Company, Indianapolis; S. Banerjee, MD, Bristol-Myers Squibb. Address correspondence to Dr. M.C. Genovese, James W. Raitt Professor of Medicine, Co-Chief Division of Immunology and Rheumatology, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication October 1, 2015.
Subhashis Banerjee
From the Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California; Eli Lilly and Company, Indianapolis, Indiana; Bristol-Myers Squibb, Princeton, New Jersey, USA. Funded by Eli Lilly and Company. M.C. Genovese has received grants and consulting support from Eli Lilly and Company. D.K. Braun, J.S. Erickson, P.Y. Berclaz, M.P. Heffernan, and H. Carlier are employees of Eli Lilly and Company and own stock or stock options in the company. S. Banerjee is a former employee of Eli Lilly and Company and owns stock in the company. M.C. Genovese, MD, James W. Raitt Professor of Medicine, Co-Chief of Division of Immunology and Rheumatology, Stanford University School of Medicine; D.K. Braun, MD, Medical Fellow; Eli Lilly and Company; J.S. Erickson, PhD, Statistician, Eli Lilly and Company; P.Y. Berclaz, MD, Senior Medical Director, Eli Lilly and Company; M.P. Heffernan, MD, Senior Medical Director, Eli Lilly and Company; H. Carlier, MD, Senior Medical Advisor, Eli Lilly and Company, Indianapolis; S. Banerjee, MD, Bristol-Myers Squibb. Address correspondence to Dr. M.C. Genovese, James W. Raitt Professor of Medicine, Co-Chief Division of Immunology and Rheumatology, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication October 1, 2015.
Michael P. Heffernan
From the Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California; Eli Lilly and Company, Indianapolis, Indiana; Bristol-Myers Squibb, Princeton, New Jersey, USA. Funded by Eli Lilly and Company. M.C. Genovese has received grants and consulting support from Eli Lilly and Company. D.K. Braun, J.S. Erickson, P.Y. Berclaz, M.P. Heffernan, and H. Carlier are employees of Eli Lilly and Company and own stock or stock options in the company. S. Banerjee is a former employee of Eli Lilly and Company and owns stock in the company. M.C. Genovese, MD, James W. Raitt Professor of Medicine, Co-Chief of Division of Immunology and Rheumatology, Stanford University School of Medicine; D.K. Braun, MD, Medical Fellow; Eli Lilly and Company; J.S. Erickson, PhD, Statistician, Eli Lilly and Company; P.Y. Berclaz, MD, Senior Medical Director, Eli Lilly and Company; M.P. Heffernan, MD, Senior Medical Director, Eli Lilly and Company; H. Carlier, MD, Senior Medical Advisor, Eli Lilly and Company, Indianapolis; S. Banerjee, MD, Bristol-Myers Squibb. Address correspondence to Dr. M.C. Genovese, James W. Raitt Professor of Medicine, Co-Chief Division of Immunology and Rheumatology, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication October 1, 2015.
Hilde Carlier
From the Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California; Eli Lilly and Company, Indianapolis, Indiana; Bristol-Myers Squibb, Princeton, New Jersey, USA. Funded by Eli Lilly and Company. M.C. Genovese has received grants and consulting support from Eli Lilly and Company. D.K. Braun, J.S. Erickson, P.Y. Berclaz, M.P. Heffernan, and H. Carlier are employees of Eli Lilly and Company and own stock or stock options in the company. S. Banerjee is a former employee of Eli Lilly and Company and owns stock in the company. M.C. Genovese, MD, James W. Raitt Professor of Medicine, Co-Chief of Division of Immunology and Rheumatology, Stanford University School of Medicine; D.K. Braun, MD, Medical Fellow; Eli Lilly and Company; J.S. Erickson, PhD, Statistician, Eli Lilly and Company; P.Y. Berclaz, MD, Senior Medical Director, Eli Lilly and Company; M.P. Heffernan, MD, Senior Medical Director, Eli Lilly and Company; H. Carlier, MD, Senior Medical Advisor, Eli Lilly and Company, Indianapolis; S. Banerjee, MD, Bristol-Myers Squibb. Address correspondence to Dr. M.C. Genovese, James W. Raitt Professor of Medicine, Co-Chief Division of Immunology and Rheumatology, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu. Accepted for publication October 1, 2015.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis
Mark C. Genovese, Daniel K. Braun, Janelle S. Erickson, Pierre-Yves Berclaz, Subhashis Banerjee, Michael P. Heffernan, Hilde Carlier
The Journal of Rheumatology Dec 2015, jrheum.140831; DOI: 10.3899/jrheum.140831
Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis
Mark C. Genovese, Daniel K. Braun, Janelle S. Erickson, Pierre-Yves Berclaz, Subhashis Banerjee, Michael P. Heffernan, Hilde Carlier
The Journal of Rheumatology Dec 2015, jrheum.140831; DOI: 10.3899/jrheum.140831